Important Class Action Update for Applied Therapeutics Investors
Significant Legal Opportunity for Investors in Applied Therapeutics
Investors who have experienced significant losses in Applied Therapeutics, Inc. (NASDAQ: APLT) during a designated class period have a chance to take action. A recent announcement from a prominent law firm indicates that investors can apply to be lead plaintiffs in a class action lawsuit against the company. This opportunity arises due to allegations of misleading practices and failure to adhere to clinical trial protocols.
Understanding the Class Action Lawsuit
The class action lawsuit, known as Alexandru v. Applied Therapeutics, Inc., has been filed in response to alleged violations of the Securities Exchange Act of 1934. Specifically, the claims suggest that Applied Therapeutics, a clinical-stage biopharmaceutical company, may have misled investors about its adherence to essential trial protocols.
Key Allegations Against Applied Therapeutics
According to the details shared in the class action complaint, the company submitted a New Drug Application (NDA) for its product, govorestat, which is intended for treating Classic Galactosemia. However, the lawsuit contends that throughout the class period, Applied Therapeutics did not properly follow clinical practices, which raised questions about the reliability of the trial data presented to the FDA.
On a significant date in the timeline, if you're an APLT investor, you'll want to note that the FDA issued a Complete Response Letter, indicating issues with the NDA. This decision resulted in a steep decline of more than 80% in the stock price over just three trading sessions. Furthermore, further revelations about warnings issued by the FDA regarding electronic data capture and dosing errors led to an additional drop of over 26% in stock value.
How to Get Involved as a Lead Plaintiff
If you believe you are qualified and wish to pursue a lead plaintiff role in this class action lawsuit, it’s essential to note certain eligibility criteria. The Private Securities Litigation Reform Act of 1995 permits investors who acquired Applied Therapeutics securities during the class period to seek lead plaintiff status. This role is vital as it directs the lawsuit on behalf of all affected investors and can aid in securing justice and compensation for losses incurred.
About Robbins Geller Law Firm
Robbins Geller Rudman & Dowd LLP, the firm behind the announcement, is recognized as one of the premier law firms focused on securities fraud cases. Over the years, they have achieved notable success in securing financial recoveries for investors, totaling billions across various class action cases. Their expansive network of attorneys is well-equipped to handle large-scale litigation, ensuring that investor interests are vigorously represented.
Contacting the Law Firm
If you are an investor interested in more information or seeking to initiate your claim, you can contact Robbins Geller by reaching out to their offices. Various attorneys are available to assist, ensuring that you receive the guidance necessary to navigate this legal process.
Robbins Geller Rudman & Dowd LLP offices are located in a major city and are open for communication. By calling their office directly, investors can gain clarity on their options and get started on the process. Remember that acting soon is vital, as deadlines are approaching.
Frequently Asked Questions
What is the class action lawsuit against Applied Therapeutics about?
The lawsuit alleges that the company provided misleading information regarding its clinical trials and failed to adhere to properly established protocols, impacting investor trust.
How can investors participate in the lawsuit?
Investors who experienced losses during the class period can apply to be lead plaintiffs or join the class by providing their information to the law firm representing the case.
What happens if I become a lead plaintiff?
As a lead plaintiff, you will represent the interests of all investors in the class action and play a key role in directing the case's development and strategy.
Is there a cost to join this lawsuit?
Typically, there are no upfront costs to join a class action lawsuit. Legal fees are usually contingent upon winning the case, meaning payment is taken from any settlements or judgments obtained.
Where can I get more information about my rights as an investor?
You can obtain more information by contacting the law firm directly or visiting their website for details on how to proceed with your claim.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.